Though, usually, most women get nausea after taking misoprostol. It can start after the first pill itself misoprostol may make it worse. More than half the women who take abortion pills say they experienced nausea. Rare (0.01% to 0.1%): Erythema nodosum, erythroderma, toxic epidermal necrolysis, urticariaįrequency not reported: Alopecia, dermatitis, diaphoresis/increased sweating Cardiovascularįrequency not reported: Amniotic fluid embolism, arrhythmia, arterial thrombosis, cardiovascular accidents, cerebrovascular accident, chest pain, coronary artery spasm, edema, hypertension, hypotension, increased cardiac enzymes, myocardial infarction/fatal myocardial infarction, pallor, phlebitis, severe hypotension, thromboembolic events Hypersensitivityįrequency not reported: Anaphylactic reaction, anaphylaxis, hypersensitivity Respiratoryįrequency not reported: Bronchitis, bronchospasm, dyspnea, epistaxis, pneumonia, pulmonary embolism, upper respiratory tract infection Metabolicįrequency not reported: Appetite change, gout, increased alkaline phosphatase, increased nitrogen, severe dehydration, thirst, weight changes Hematologicįrequency not reported: Abnormal differential, anemia, increased erythrocyte sedimentation rate, purpura, thrombocytopenia Psychiatricįrequency not reported: Anxiety, confusion, depression, loss of libido, neurosis Musculoskeletalįrequency not reported: Arthralgia, back pain, myalgia, muscle cramps.Caution: If abdominal or back pain is so extreme that you are unable to stand up, seek immediate help from a doctor. Very rare (less than 0.01%): Serious/fatal septic shock, serious/fatal toxic shockįrequency not reported: Aches/pains, asthenia, deafness, earache, fatigue, incomplete abortion, premature birth, retained placenta, rigors, tinnitus Dermatologic
Rare (0.01% to 0.1%): Birth defects, chills, fetal death, malaise įrequency not reported: Abnormal taste, drowsiness, neuropathy, syncope OtherĬommon (1% to 10%): Infection following abortion Vagal symptoms included hot flush, dizziness, and chills. Uncommon (0.1% to 1%): Light to moderate crampingįrequency not reported: Dysphagia, gastrointestinal bleeding, gastrointestinal inflammation and infection, gingivitis, loose stools, profound diarrhea, rectal disorder, reflux Nervous system Very common (10% or more): Diarrhea (up to 40%), abdominal pain (up to 20%)Ĭommon (1% to 10%): Constipation, dyspepsia, flatulence, nausea, vomiting Gastrointestinalĭiarrhea usually occurred early in treatment, and was typically dose-related, self-limiting, and required discontinuation in approximately 2% of patients in clinical trials.
Heavy bleeding required hemostatic curettage in up to 1.4% of patients. Uterine contractions/cramping usually occurred within hours of oral administration. Uncommon (0.1% to 1%): Cramps, dysmenorrhea, hypermenorrhea, intermenstrual bleeding, menstrual disorder, spotting, vaginal hemorrhageįrequency not reported: Abnormal uterine contractions, breast pain, dysuria, hematuria, impotence, polyuria, postmenopausal vaginal bleeding, urinary tract infection, uterine hemorrhage, uterine perforation, uterine rupture Very common (10% or more): Uterine contractions/cramping (up to 45%)Ĭommon (1% to 10%): Endometritis, heavy bleeding, pelvic inflammatory disease The most commonly reported side effects included uterine contractions/cramping, diarrhea, and abdominal pain. For Healthcare ProfessionalsĪpplies to misoprostol: oral tablet. 1Īdvise patients of the abortifacient property of misoprostol and warn them not to give the drug to others because of the danger to women of childbearing potential should the drug be taken by mistake. 1 Misoprostol should only be initiated on the second or third day of the next normal menstrual period.
1 In such women, pregnancy must be excluded before the start of treatment and prevented thereafter by use of reliable contraception. Misoprostol should not be used for reducing the risk of NSAIA-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAIA, or is at high risk of developing gastric ulceration. Misoprostol should not be taken by pregnant women to reduce the risk of nonsteroidal anti-inflammatory agent (NSAIA)-induced ulcers. Uterine rupture reported when misoprostol was administered in pregnant women to induce labor or to induce abortion risk increases with advancing gestational age and with prior uterine surgery, including cesarean delivery.
May cause serious fetal harm (e.g., birth defects, abortion, premature birth, uterine rupture).
0 kommentar(er)
